Quantum BioPharma Lawsuit Against Major Banks Featured in CTV W5 Investigation on Market Manipulation

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in the second part of CTV News' investigative program W5's three-part series examining the company's allegations of stock spoofing tied to its $700 million lawsuit against CIBC and RBC. The segment, reported by award-winning journalist Jon Woodward, highlights Quantum BioPharma's claims of widespread market manipulation and its impact on the company's efforts to advance Lucid-MS, a potential multiple-sclerosis treatment.

CEO Zeeshan Saeed and Co-Executive Chair Anthony Durkacz reiterated their concerns about the alleged activity during the W5 segment, noting that Canadian exchange data cited in the lawsuit points to millions of purportedly illegal orders originating from bank platforms. The company maintains that these activities have significantly affected its stock performance and ability to fund research into critical medical treatments.

The importance of this investigation extends beyond Quantum BioPharma's specific case, potentially revealing systemic issues in financial markets that could affect investor confidence and capital formation for innovative companies. Market manipulation allegations involving major financial institutions like CIBC and RBC raise questions about market integrity and regulatory oversight, particularly when such activities allegedly target companies developing treatments for serious medical conditions.

Quantum BioPharma's lead compound, Lucid-MS, represents a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company alleges that the market manipulation has hindered its ability to advance this potentially groundbreaking treatment through clinical development stages. For investors and the biopharmaceutical industry, this case illustrates how alleged financial misconduct can directly impact medical innovation and patient access to new therapies.

The company's latest news and updates relating to QNTM are available in its newsroom at https://ibn.fm/QNTM. The full press release about the W5 coverage can be viewed at https://ibn.fm/t3Tex. These developments come as Quantum BioPharma continues to build its portfolio of innovative assets for treating challenging neurodegenerative and metabolic disorders, including through its strategic investments subsidiary FSD Strategic Investments Inc.

For the broader investment community, this investigation highlights the ongoing challenges of ensuring fair and transparent markets, particularly for smaller public companies that may be more vulnerable to manipulative trading practices. The outcome of Quantum BioPharma's lawsuit could set important precedents for how financial institutions monitor and prevent potentially manipulative trading activities on their platforms, with implications for market regulation and investor protection across North American exchanges.